Skip to main content
Premium Trial:

Request an Annual Quote

Bayer and Burrill Will Back Genomics-Based Diagnostics Ventures with $50 Million Fund

NEW YORK, Jan. 8 — Bayer Diagnostic and Burrill & Company said Tuesday that they had formed a new $50 million venture capital fund for diagnostic research. The fund particularly seeks to back new applications of pharmacogenomic and proteomic technology in the diagnostic field.

 

The new Burrill Diagnostics Capital Fund has an initial closing of $25 million. Additional fundraising is projected to conclude by June 2002.

 

The fund was launched to promote technological advances in the business of disease diagnostics and treatment monitoring and to provide growth capital to companies in this sector. It will focus on high-growth areas such as device miniaturization, pharmacogenomic testing, and non-invasive testing, said Bayer Diagnostics president Rolf Classon in a statement.

 

Other tools mentioned by the fund's backers include technologies that allow for disease susceptibility genotyping and for genetic stratification of patients in clinical trials.

 

San Francisco-based Burrill & Company has a family of life science funds, including funds in agricultural biotechnology, nutraceuticals, general biotechnology and biomaterials.

 

Bayer Innovation, a subsidiary of Bayer AG, will be the partner in the new fund.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.